Immunocore Holdings Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Public

  • Employees
  • 524

Employees

  • Stock Symbol
  • IMCR

Stock Symbol

  • Share Price
  • $26.38
  • (As of Friday Closing)

Immunocore Holdings General Information

Description

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 92 Park Drive
  • Milton Park, Oxon
  • Abingdon OX14 4RY
  • England, United Kingdom
+44 01235
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 92 Park Drive
  • Milton Park, Oxon
  • Abingdon OX14 4RY
  • England, United Kingdom
+44 01235

Immunocore Holdings Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Immunocore Holdings Stock Performance

As of 20-Nov-2026, Immunocore Holdings’s stock price is $26.38. Its current market cap is $1.36B with 51.7M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$26.38 $26.60 $25.61 - $40.71 $1.36B 51.7M 449K -$0.64

Immunocore Holdings Financials Summary

As of 30-Sep-2026, Immunocore Holdings has a trailing 12-month revenue of $429M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,114,641 1,297,420 1,055,748 3,019,480
Revenue 429,304 400,016 310,202 249,428
EBITDA (15,537) (20,144) (55,507) (69,632)
Net Income (32,119) (35,514) (51,087) (55,287)
Total Assets 1,129,239 1,067,269 1,009,506 597,001
Total Debt 435,737 436,687 432,722 85,010
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Immunocore Holdings Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Immunocore Holdings‘s full profile, request access.

Request a free trial

Immunocore Holdings Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Immunocore Holdings‘s full profile, request access.

Request a free trial

Immunocore Holdings Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developin
Drug Discovery
Abingdon, United Kingdom
524 As of 2025

Cambridge, MA
 

Lexington, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Immunocore Holdings Competitors (73)

One of Immunocore Holdings’s 73 competitors is Sarepta Therapeutics, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sarepta Therapeutics Formerly VC-backed Cambridge, MA
Aldeyra Therapeutics Formerly VC-backed Lexington, MA
TME Pharma Formerly VC-backed Berlin, Germany
Ayala Pharmaceuticals Corporation Wilmington, DE
Sharp Therapeutics (Biotechnology) Formerly VC-backed Pittsburgh, PA
You’re viewing 5 of 73 competitors. Get the full list »

Immunocore Holdings Patents

Immunocore Holdings Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202510176-D0 Multispecific molecules Pending 25-Jun-2025
GB-202418912-D0 Specific binding molecules Pending 20-Dec-2024
WO-2026132488-A1 Specific binding molecules Pending 20-Dec-2024
WO-2026110106-A1 Intravenous solution stabilizer Pending 22-Nov-2024
GB-202411647-D0 Method Inactive 07-Aug-2024 C07K16/2809
To view Immunocore Holdings’s complete patent history, request access »

Immunocore Holdings Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Immunocore Holdings Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Immunocore Holdings‘s full profile, request access.

Request a free trial

Immunocore Holdings ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Immunocore Holdings’s complete esg history, request access »

Immunocore Holdings Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Immunocore Ireland Dublin, Ireland 2018

Immunocore Holdings FAQs

  • When was Immunocore Holdings founded?

    Immunocore Holdings was founded in 1999.

  • Where is Immunocore Holdings headquartered?

    Immunocore Holdings is headquartered in Abingdon, United Kingdom.

  • What is the size of Immunocore Holdings?

    Immunocore Holdings has 524 total employees.

  • What industry is Immunocore Holdings in?

    Immunocore Holdings’s primary industry is Drug Discovery.

  • Is Immunocore Holdings a private or public company?

    Immunocore Holdings is a Public company.

  • What is Immunocore Holdings’s stock symbol?

    The ticker symbol for Immunocore Holdings is IMCR.

  • What is the current stock price of Immunocore Holdings?

    As of 20-Nov-2026 the stock price of Immunocore Holdings is $26.38.

  • What is the current market cap of Immunocore Holdings?

    The current market capitalization of Immunocore Holdings is $1.36B.

  • What is Immunocore Holdings’s current revenue?

    The trailing twelve month revenue for Immunocore Holdings is $429M.

  • Who are Immunocore Holdings’s competitors?

    Sarepta Therapeutics, Aldeyra Therapeutics, TME Pharma, Ayala Pharmaceuticals, and Sharp Therapeutics (Biotechnology) are some of the 73 competitors of Immunocore Holdings.

  • What is Immunocore Holdings’s annual earnings per share (EPS)?

    Immunocore Holdings’s EPS for 12 months was -$0.64.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process